Supplementary Figure 4 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment

Supplementary Figure 4 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment

<p>Figure S4 shows the gating strategy of monocytes sorted from BAFF-expressing and control tumors</p>

Tallennettuna:

Bibliografiset tiedot
Päätekijä:	Wei Liu (20030) (author)
Muut tekijät:	Paweł Stachura (8480817) (author), Haifeng C. Xu (7373933) (author), Renáta Váraljai (15194397) (author), Prashant Shinde (3707917) (author), Nikkitha Umesh Ganesh (15194400) (author), Matthias Mack (148002) (author), Anke Van Lierop (15194403) (author), Anfei Huang (461244) (author), Balamurugan Sundaram (440602) (author), Karl S. Lang (8444004) (author), Daniel Picard (14938665) (author), Ute Fischer (15194406) (author), Marc Remke (3508145) (author), Bernhard Homey (31953) (author), Alexander Roesch (2416078) (author), Dieter Häussinger (15194409) (author), Philipp A. Lang (7373936) (author), Arndt Borkhardt (2891) (author), Aleksandra A. Pandyra (8444013) (author)
Julkaistu:	2025
Aiheet:	Cancer Tumor Biology Immuno-oncology Immunology Cytokines Myeloid-derived suppressor cells NK cells Tumor immunology animal models Tumor-associated macrophages Skin Cancers Melanoma Tumor Microenvironment Cytokines and the microenvironment
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia

Supplementary Figure 1 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
Tekijä: Wei Liu (20030)
Julkaistu: (2025)

Supplementary Figure 2 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
Tekijä: Wei Liu (20030)
Julkaistu: (2025)

Supplementary Figure 3 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
Tekijä: Wei Liu (20030)
Julkaistu: (2025)

Supplementary Figure 5 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
Tekijä: Wei Liu (20030)
Julkaistu: (2025)

Supplementary Figure 6 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
Tekijä: Wei Liu (20030)
Julkaistu: (2025)

Supplementary Figure7 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
Tekijä: Wei Liu (20030)
Julkaistu: (2025)

Supplementary Table 1 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
Tekijä: Wei Liu (20030)
Julkaistu: (2025)

Supplementary Table 2 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
Tekijä: Wei Liu (20030)
Julkaistu: (2025)

Supplementary Table 3 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
Tekijä: Wei Liu (20030)
Julkaistu: (2025)

Supplementary figures and tables FTS1 from Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial
Tekijä: Daniel S. Green (15047598)
Julkaistu: (2025)

Supplementary Figures SF1-SF9 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
Tekijä: Robin M. Hallett (15037427)
Julkaistu: (2025)

Supplementary Tables ST1-ST6 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
Tekijä: Robin M. Hallett (15037427)
Julkaistu: (2025)

Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
Tekijä: Sonia A. Patel (15055688)
Julkaistu: (2025)

Supplementary Figure S2 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
Tekijä: Sonia A. Patel (15055688)
Julkaistu: (2025)

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
Tekijä: Sonia A. Patel (15055688)
Julkaistu: (2025)

Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
Tekijä: Sonia A. Patel (15055688)
Julkaistu: (2025)

Supplementary Figure S5 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
Tekijä: Sonia A. Patel (15055688)
Julkaistu: (2025)

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Tekijä: Dahihm Kim (16546203)
Julkaistu: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Tekijä: Dahihm Kim (16546203)
Julkaistu: (2025)

Figure S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Tekijä: Dahihm Kim (16546203)
Julkaistu: (2025)

Figure S4 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Tekijä: Dahihm Kim (16546203)
Julkaistu: (2025)

Figure S5 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Tekijä: Dahihm Kim (16546203)
Julkaistu: (2025)

Table S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Tekijä: Dahihm Kim (16546203)
Julkaistu: (2025)

Table S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Tekijä: Dahihm Kim (16546203)
Julkaistu: (2025)

Supplementary Data 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
Tekijä: Alexander N. Shoushtari (15023909)
Julkaistu: (2025)

Supplementary video from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Tekijä: Min Wu (14962986)
Julkaistu: (2025)

Table S1 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Tekijä: Min Wu (14962986)
Julkaistu: (2025)

Table S2 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Tekijä: Min Wu (14962986)
Julkaistu: (2025)

Table S3 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Tekijä: Min Wu (14962986)
Julkaistu: (2025)

Supplementary Figures from Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets
Tekijä: Defne Bayik (14961098)
Julkaistu: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Tekijä: Hansol Lee (15054787)
Julkaistu: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Tekijä: Hansol Lee (15054787)
Julkaistu: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Tekijä: Hansol Lee (15054787)
Julkaistu: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Tekijä: Hansol Lee (15054787)
Julkaistu: (2025)

Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
Tekijä: James S. Wilmott (15008931)
Julkaistu: (2025)

Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
Tekijä: James S. Wilmott (15008931)
Julkaistu: (2025)

Supplementary file 1_Single-cell transcriptomics identifies FOSL1-regulated IGFBP3+ melanoma subtype as a neuro-immunoregulatory signaling hub facilitating tumor progression.docx
Tekijä: Wenjia Ge (22687361)
Julkaistu: (2025)

Supplementary Table S1 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Tekijä: Jonathan M.J. Derry (16648337)
Julkaistu: (2025)

Supplementary Table S2 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Tekijä: Jonathan M.J. Derry (16648337)
Julkaistu: (2025)

Supplementary Table S3 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Tekijä: Jonathan M.J. Derry (16648337)
Julkaistu: (2025)

Cannot write session to /tmp/vufind_sessions/sess_h8gffvv4fcgse0m46oskl50q7r